Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia

7 clinical trials · Condition

Record	Firm	Date
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (NCT02614066)	Kite, A Gilead Company	2016-03-07
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT02625480)	Kite, A Gilead Company	2016-02-01
Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (NCT02412306)	Amgen	2015-06-04
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (NCT02013167)	Amgen	2014-01-03
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (NCT02187354)	Amgen

Every clearance here is in the API, with alerts when new ones post.